- Home
- FHN vs EXEL Comparison
FHN vs EXEL Comparison
Compare FHN & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- EXEL
- Stock Information
- Founded
- FHN 1864
- EXEL 1994
- Country
- FHN United States
- EXEL United States
- Employees
- FHN N/A
- EXEL N/A
- Industry
- FHN Major Banks
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FHN Finance
- EXEL Health Care
- Exchange
- FHN Nasdaq
- EXEL Nasdaq
- Market Cap
- FHN 11.0B
- EXEL 10.4B
- IPO Year
- FHN N/A
- EXEL 2000
- Fundamental
- Price
- FHN $21.53
- EXEL $40.81
- Analyst Decision
- FHN Buy
- EXEL Buy
- Analyst Count
- FHN 20
- EXEL 24
- Target Price
- FHN $24.10
- EXEL $44.73
- AVG Volume (30 Days)
- FHN 15.6M
- EXEL 3.2M
- Earning Date
- FHN 10-15-2025
- EXEL 11-04-2025
- Dividend Yield
- FHN 2.79%
- EXEL N/A
- EPS Growth
- FHN 19.36
- EXEL 53.55
- EPS
- FHN 1.65
- EXEL 2.38
- Revenue
- FHN $3,184,000,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- FHN $12.70
- EXEL $9.14
- Revenue Next Year
- FHN $2.54
- EXEL $12.51
- P/E Ratio
- FHN $13.01
- EXEL $17.17
- Revenue Growth
- FHN 3.75
- EXEL 9.93
- 52 Week Low
- FHN $15.19
- EXEL $31.90
- 52 Week High
- FHN $23.70
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- FHN 49.88
- EXEL 58.21
- Support Level
- FHN $20.95
- EXEL $36.00
- Resistance Level
- FHN $21.70
- EXEL $41.55
- Average True Range (ATR)
- FHN 0.47
- EXEL 1.39
- MACD
- FHN 0.11
- EXEL 0.27
- Stochastic Oscillator
- FHN 83.00
- EXEL 87.63
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.